Cargando…

Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data

BACKGROUND: RNA-seq has spurred important gene fusion discoveries in a number of different cancers, including lung, prostate, breast, brain, thyroid and bladder carcinomas. Gene fusion discovery can potentially lead to the development of novel treatments that target the underlying genetic abnormalit...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Nameeta, Lankerovich, Michael, Lee, Hwahyung, Yoon, Jae-Geun, Schroeder, Brett, Foltz, Greg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046790/
https://www.ncbi.nlm.nih.gov/pubmed/24261984
http://dx.doi.org/10.1186/1471-2164-14-818
_version_ 1782480313319948288
author Shah, Nameeta
Lankerovich, Michael
Lee, Hwahyung
Yoon, Jae-Geun
Schroeder, Brett
Foltz, Greg
author_facet Shah, Nameeta
Lankerovich, Michael
Lee, Hwahyung
Yoon, Jae-Geun
Schroeder, Brett
Foltz, Greg
author_sort Shah, Nameeta
collection PubMed
description BACKGROUND: RNA-seq has spurred important gene fusion discoveries in a number of different cancers, including lung, prostate, breast, brain, thyroid and bladder carcinomas. Gene fusion discovery can potentially lead to the development of novel treatments that target the underlying genetic abnormalities. RESULTS: In this study, we provide comprehensive view of gene fusion landscape in 185 glioblastoma multiforme patients from two independent cohorts. Fusions occur in approximately 30-50% of GBM patient samples. In the Ivy Center cohort of 24 patients, 33% of samples harbored fusions that were validated by qPCR and Sanger sequencing. We were able to identify high-confidence gene fusions from RNA-seq data in 53% of the samples in a TCGA cohort of 161 patients. We identified 13 cases (8%) with fusions retaining a tyrosine kinase domain in the TCGA cohort and one case in the Ivy Center cohort. Ours is the first study to describe recurrent fusions involving non-coding genes. Genomic locations 7p11 and 12q14-15 harbor majority of the fusions. Fusions on 7p11 are formed in focally amplified EGFR locus whereas 12q14-15 fusions are formed by complex genomic rearrangements. All the fusions detected in this study can be further visualized and analyzed using our website: http://ivygap.swedish.org/fusions. CONCLUSIONS: Our study highlights the prevalence of gene fusions as one of the major genomic abnormalities in GBM. The majority of the fusions are private fusions, and a minority of these recur with low frequency. A small subset of patients with fusions of receptor tyrosine kinases can benefit from existing FDA approved drugs and drugs available in various clinical trials. Due to the low frequency and rarity of clinically relevant fusions, RNA-seq of GBM patient samples will be a vital tool for the identification of patient-specific fusions that can drive personalized therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2164-14-818) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4046790
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40467902014-06-06 Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data Shah, Nameeta Lankerovich, Michael Lee, Hwahyung Yoon, Jae-Geun Schroeder, Brett Foltz, Greg BMC Genomics Research Article BACKGROUND: RNA-seq has spurred important gene fusion discoveries in a number of different cancers, including lung, prostate, breast, brain, thyroid and bladder carcinomas. Gene fusion discovery can potentially lead to the development of novel treatments that target the underlying genetic abnormalities. RESULTS: In this study, we provide comprehensive view of gene fusion landscape in 185 glioblastoma multiforme patients from two independent cohorts. Fusions occur in approximately 30-50% of GBM patient samples. In the Ivy Center cohort of 24 patients, 33% of samples harbored fusions that were validated by qPCR and Sanger sequencing. We were able to identify high-confidence gene fusions from RNA-seq data in 53% of the samples in a TCGA cohort of 161 patients. We identified 13 cases (8%) with fusions retaining a tyrosine kinase domain in the TCGA cohort and one case in the Ivy Center cohort. Ours is the first study to describe recurrent fusions involving non-coding genes. Genomic locations 7p11 and 12q14-15 harbor majority of the fusions. Fusions on 7p11 are formed in focally amplified EGFR locus whereas 12q14-15 fusions are formed by complex genomic rearrangements. All the fusions detected in this study can be further visualized and analyzed using our website: http://ivygap.swedish.org/fusions. CONCLUSIONS: Our study highlights the prevalence of gene fusions as one of the major genomic abnormalities in GBM. The majority of the fusions are private fusions, and a minority of these recur with low frequency. A small subset of patients with fusions of receptor tyrosine kinases can benefit from existing FDA approved drugs and drugs available in various clinical trials. Due to the low frequency and rarity of clinically relevant fusions, RNA-seq of GBM patient samples will be a vital tool for the identification of patient-specific fusions that can drive personalized therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2164-14-818) contains supplementary material, which is available to authorized users. BioMed Central 2013-11-22 /pmc/articles/PMC4046790/ /pubmed/24261984 http://dx.doi.org/10.1186/1471-2164-14-818 Text en © Shah et al.; licensee BioMed Central Ltd. 2013 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Shah, Nameeta
Lankerovich, Michael
Lee, Hwahyung
Yoon, Jae-Geun
Schroeder, Brett
Foltz, Greg
Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data
title Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data
title_full Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data
title_fullStr Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data
title_full_unstemmed Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data
title_short Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data
title_sort exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046790/
https://www.ncbi.nlm.nih.gov/pubmed/24261984
http://dx.doi.org/10.1186/1471-2164-14-818
work_keys_str_mv AT shahnameeta explorationofthegenefusionlandscapeofglioblastomausingtranscriptomesequencingandcopynumberdata
AT lankerovichmichael explorationofthegenefusionlandscapeofglioblastomausingtranscriptomesequencingandcopynumberdata
AT leehwahyung explorationofthegenefusionlandscapeofglioblastomausingtranscriptomesequencingandcopynumberdata
AT yoonjaegeun explorationofthegenefusionlandscapeofglioblastomausingtranscriptomesequencingandcopynumberdata
AT schroederbrett explorationofthegenefusionlandscapeofglioblastomausingtranscriptomesequencingandcopynumberdata
AT foltzgreg explorationofthegenefusionlandscapeofglioblastomausingtranscriptomesequencingandcopynumberdata